Form 4: Rigel Pharmaceuticals EVP & CFO Dean L. Schorno Sells Shares to Cover Tax Obligations

Dean L. Schorno, EVP & CFO of Rigel Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• Dean L. Schorno, the EVP & Chief Financial Officer of Rigel Pharmaceuticals, sold shares of common stock on February 4th and 5th, 2025.
• The sales were executed to cover tax withholding obligations due upon the vesting of Restricted Stock Units.
• On February 4th, 2025, 2,036 shares were sold at a price of $20.921 per share.
• On February 5th, 2025, 1,734 shares were sold at a price of $21.926 per share.
• Following these transactions, Schorno directly owns 57,235 shares of Rigel Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral. The filing simply reports the sale of shares to cover tax obligations, which is a routine transaction. There is no indication of positive or negative sentiment towards the company's prospects.

Management Comments

• These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units.
• Such 'sales to cover' were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, although it is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Dean L. Schorno, EVP & CFO, Form 4, Share Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership